| scholarly article | Q13442814 |
| P2093 | author name string | Xiaoming Yang | |
| Jihong Sun | |||
| Lumin Chen | |||
| P2860 | cites work | Response to Facciorusso et al | Q87245018 |
| Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4 cm) and in high-risk locations | Q87363408 | ||
| Global cancer statistics | Q22241238 | ||
| Optimal combination of antiangiogenic therapy for hepatocellular carcinoma | Q26799458 | ||
| Current and future treatments for hepatocellular carcinoma | Q26801211 | ||
| Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis | Q26864261 | ||
| Current systemic treatment of hepatocellular carcinoma: A review of the literature | Q27026036 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1α/VEGFA | Q28483727 | ||
| Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes | Q28538311 | ||
| Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy | Q28542027 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Radiofrequency ablation of hepatocellular carcinoma: Current status | Q30478030 | ||
| Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial? | Q87245014 | ||
| Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. | Q30512830 | ||
| The combined effect of radiofrequency and ethanol ablation in the management of large hepatocellular carcinoma | Q30783858 | ||
| Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications | Q33373882 | ||
| Principles of and Advances in Percutaneous Ablation | Q33805803 | ||
| Radiofrequency heat-enhanced chemotherapy for breast cancer: towards interventional molecular image-guided chemotherapy | Q34195652 | ||
| Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma | Q34207863 | ||
| Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors | Q34399657 | ||
| Thermal ablation of tumours: biological mechanisms and advances in therapy. | Q34406134 | ||
| Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study | Q34495478 | ||
| Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection | Q34503100 | ||
| Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection | Q34720013 | ||
| Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy. | Q34725980 | ||
| Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression | Q34876404 | ||
| Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma | Q35010394 | ||
| Interventional Radiological Treatment of Hepatocellular Carcinoma: An Update | Q35675131 | ||
| Multimodal treatment of hepatocellular carcinoma (HCC). | Q35834098 | ||
| Resection and liver transplantation for hepatocellular carcinoma. | Q36140302 | ||
| Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: Reduced tumor growth and increased animal endpoint survival in a small animal tumor model | Q36142890 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| Current status of multimodal & combination therapy for hepatocellular carcinoma | Q36436294 | ||
| Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma | Q36975036 | ||
| Combination of radiofrequency ablation and immunotherapy. | Q36991803 | ||
| Science to Practice: Can We Expand Focal Interventional Oncologic Ablation Treatments into an Effective Systemic Therapy? | Q37006322 | ||
| Immunotherapeutic approaches to hepatocellular carcinoma treatment | Q37140685 | ||
| Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature | Q37196965 | ||
| TACE versus TAE as therapy for hepatocellular carcinoma | Q37300023 | ||
| The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. | Q37357774 | ||
| Multimodal therapy for hepatocellular carcinoma: a complementary approach to liver transplantation | Q37716429 | ||
| Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation | Q37727030 | ||
| Loco-regional treatment of hepatocellular carcinoma | Q37766546 | ||
| Is Percutaneous Ethanol Injection Therapy Still Effective for Hepatocellular Carcinoma in the Era of Radiofrequency Ablation? | Q37811920 | ||
| CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement | Q37975880 | ||
| Doxil® — The first FDA-approved nano-drug: Lessons learned | Q38000876 | ||
| Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma | Q38052472 | ||
| Hyperthermia-induced drug targeting | Q38071664 | ||
| New agents on the horizon in hepatocellular carcinoma | Q38074429 | ||
| Small- and Medium-sized Hepatocellular Carcinomas: Monopolar Radiofrequency Ablation with a Multiple-Electrode Switching System—Mid-term Results | Q38091417 | ||
| Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis | Q38201145 | ||
| Advanced nanovehicles for cancer management. | Q38225024 | ||
| Ablation of hepatocellular carcinoma | Q38254702 | ||
| Surgical resection and liver transplantation for hepatocellular carcinoma | Q38447653 | ||
| Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma | Q38885580 | ||
| Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression | Q38898942 | ||
| Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. | Q39131172 | ||
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Q39585554 | ||
| Combined ethanol injection therapy and radiofrequency ablation therapy in percutaneous treatment of hepatocellular carcinoma larger than 4 cm. | Q40484234 | ||
| In situ tumor ablation creates an antigen source for the generation of antitumor immunity | Q40550098 | ||
| Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma | Q41482382 | ||
| Transarterial Chemoembolization in Combination with Local Therapies for Hepatocellular Carcinoma: A Meta-Analysis | Q41761634 | ||
| Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma. | Q41851928 | ||
| Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression‐free survival for patients with hepatocellular carcinoma | Q42286093 | ||
| Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. | Q43601180 | ||
| Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma. | Q44143177 | ||
| Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide | Q44521099 | ||
| Enlargement of thermal ablation zone by the combination of ethanol injection and radiofrequency ablation in excised bovine liver. | Q44725748 | ||
| Efficacy of combination therapies of percutaneous or laparoscopic ethanol-lipiodol injection and radiofrequency ablation. | Q45152961 | ||
| Radiofrequency Ablation: Inflammatory Changes in the Periablative Zone Can Induce Global Organ Effects, including Liver Regeneration | Q45874404 | ||
| Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation | Q46591334 | ||
| Radiofrequency Ablation of Liver Tumors in Combination with Local OK-432 Injection Prolongs Survival and Suppresses Distant Tumor Growth in the Rabbit Model with Intra- and Extrahepatic VX2 Tumors | Q46614619 | ||
| Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations | Q46743936 | ||
| Time-lag performance of radiofrequency ablation after percutaneous ethanol injection for the treatment of hepatocellular carcinoma | Q46981754 | ||
| Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size | Q47335511 | ||
| Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma | Q50927490 | ||
| Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma | Q51738380 | ||
| Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors | Q51906803 | ||
| A Comparison of US-guided Percutaneous Radiofrequency Ablation of Medium-sized Hepatocellular Carcinoma with a Cluster Electrode or a Single Electrode with a Multiple Overlapping Ablation Technique | Q53222822 | ||
| Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. | Q53247066 | ||
| Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation | Q53509282 | ||
| Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial | Q56785995 | ||
| Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma | Q57317511 | ||
| In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation | Q64126380 | ||
| Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases | Q71620935 | ||
| Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma | Q72992727 | ||
| Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma | Q73074276 | ||
| Percutaneous tumor ablation: increased coagulation by combining radio-frequency ablation and ethanol instillation in a rat breast tumor model | Q73282091 | ||
| Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results | Q74067155 | ||
| Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features | Q78439686 | ||
| Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits | Q79166964 | ||
| Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin | Q79777704 | ||
| Radiofrequency ablation: variability in heat sensitivity in tumors and tissues | Q80313163 | ||
| Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice | Q80642628 | ||
| Systemic treatment of colorectal cancer | Q81253030 | ||
| Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study | Q86000666 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 78-84 | |
| P577 | publication date | 2015-10-12 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status | |
| P478 | volume | 370 |
| Q49985544 | 131I-Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors via Hepatic Artery Embolization. |
| Q92711036 | Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy |
| Q29248618 | Current applications and future prospects of nanomaterials in tumor therapy |
| Q52568926 | Effect of Microbubble-Enhanced Ultrasound on Radiofrequency Ablation of Rabbit Liver |
| Q50076590 | Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. |
| Q39274269 | Innovative Techniques for Image-Guided Ablation of Benign Thyroid Nodules: Combined Ethanol and Radiofrequency Ablation |
| Q26744830 | Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma |
| Q64084332 | Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram |
| Q38749532 | Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma |
| Q92841208 | Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma |
| Q39403724 | The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma |
Search more.